Baird Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney maintains an Outperform rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $157 to $180.
August 02, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney maintains an Outperform rating on Neurocrine Biosciences and raises the price target from $157 to $180.
The raised price target and maintained Outperform rating by a reputable analyst are positive signals for investors, likely leading to a short-term increase in NBIX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100